Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Engineering a universal oncolytic virus boost in adoptive T cell therapies for cancer

FY 2019-20

Summary
Advances in cancer research have led to a field of research dedicated to using a patient's own immune system to target and treat their cancer. In general, these immunotherapies are more targeted and less toxic that traditional chemotherapies and radiation therapies. In order to "reprogram" immune cells to seek out and destroy tumour targets, we must teach these cells what to look for and how to respond when they come in contact with the tumour. A challenge in bringing these immunotherapies to the clinic is the diversity of tumour markers among and within individual patients, making it necessary for these treatments to be personalized. By using an oncolytic virus vaccine that infects only cancer cells, and engineered immune cells that target this virus, we may be able to improve the anti-tumour immune response without needing to analyze an individual's unique tumour markers first. In addition to this, the oncolytic virus has been shown to improve the immune response against the tumour which may lead to better tumour clearance. We think that this strategy may be a step towards a "universal" method of generating effective tumour-specific immune cells, and that this strategy could be used to improve immunotherapies by increasing the ability of immune cells to kill cancer cells while reducing the extent to which these therapies must be personalized on a patient-by-patient basis.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
416730
Name
Burchett Rebecca
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Engineering a universal oncolytic virus boost in adoptive T cell therapies for cancer
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Cancer Immunotherapy; Cancer Vaccines; Chimeric Antigen Receptors; Engineered T Cells; Immuno-Oncology; Oncolytic Virus; Syngeneic Mouse Models
Abstract
Advances in cancer research have led to a field of research dedicated to using a patient's own immune system to target and treat their cancer. In general, these immunotherapies are more targeted and less toxic that traditional chemotherapies and radiation therapies. In order to "reprogram" immune cells to seek out and destroy tumour targets, we must teach these cells what to look for and how to respond when they come in contact with the tumour. A challenge in bringing these immunotherapies to the clinic is the diversity of tumour markers among and within individual patients, making it necessary for these treatments to be personalized. By using an oncolytic virus vaccine that infects only cancer cells, and engineered immune cells that target this virus, we may be able to improve the anti-tumour immune response without needing to analyze an individual's unique tumour markers first. In addition to this, the oncolytic virus has been shown to improve the immune response against the tumour which may lead to better tumour clearance. We think that this strategy may be a step towards a "universal" method of generating effective tumour-specific immune cells, and that this strategy could be used to improve immunotherapies by increasing the ability of immune cells to kill cancer cells while reducing the extent to which these therapies must be personalized on a patient-by-patient basis.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Burchett, Rebecca
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2019-20) | Canada Spends